Population Pharmacokinetics Analysis of Pemigatinib in Patients With Advanced Malignancies
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Pharmacology in Drug Development"
DOI: 10.1002/cpdd.1038
Abstract: Pemigatinib is a fibroblast growth factor receptor 1–3 inhibitor used to treat cholangiocarcinoma. A compartmental population pharmacokinetics model was developed using data from 318 patients with cancer enrolled in a phase 1 dose‐escalation/dose‐expansion study, a… read more here.
Keywords: pharmacokinetics analysis; typical pemigatinib; population pharmacokinetics; model ... See more keywords